Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin

INTRODUCTION: We compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (70% intermediate SAR341402 protamine and 30% rapid SAR341402 solution) (SAR(Asp)-Mix) with its originator NovoMix 30 insulin aspart mix (NN-Mix) in adults with type 1 or type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Aravind, S. R., Singh, Kiran P., Mogylnytska, Liliia, Zalevskaya, Alsu G., Matyjaszek-Matuszek, Beata, Wernicke-Panten, Karin, Nguyên-Pascal, My-Liên, Pierre, Suzanne, Rotthaeuser, Baerbel, Kramer, Daniel, Mukherjee, Bhaswati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159382/
https://www.ncbi.nlm.nih.gov/pubmed/35650350
http://dx.doi.org/10.1007/s13300-022-01279-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159382/
https://www.ncbi.nlm.nih.gov/pubmed/35650350
http://dx.doi.org/10.1007/s13300-022-01279-z

Ejemplares similares